BioAtla Inc
BCAB
Company Profile
Business description
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Contact
11085 Torreyana Road
San DiegoCA92121
USAT: +1 858 558-0708
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
61
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,787.40 | 41.30 | -0.47% |
| CAC 40 | 7,738.42 | 75.83 | 0.99% |
| DAX 40 | 23,790.11 | 116.82 | 0.49% |
| Dow JONES (US) | 44,484.42 | 10.52 | -0.02% |
| FTSE 100 | 8,774.69 | 10.64 | -0.12% |
| HKSE | 23,949.83 | 271.58 | -1.12% |
| NASDAQ | 20,393.13 | 190.24 | 0.94% |
| Nikkei 225 | 39,732.63 | 29.85 | -0.08% |
| NZX 50 Index | 12,688.74 | 95.55 | -0.75% |
| S&P 500 | 6,227.42 | 29.41 | 0.47% |
| S&P/ASX 200 | 8,552.00 | 45.70 | -0.53% |
| SSE Composite Index | 3,450.76 | 4.03 | -0.12% |